Company intelligence / Profile preview
Tolka AI Therapeutics
Miami, Florida, United Statestolka.ai ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Preclinical
01
Overview
Tolka AI Therapeutics has received FDA approval to treat patients under an Expanded Access Program. They have treated their first patient and plan to treat 5-10 more patients under the same program. They are working toward clinical trials in the next few years with an expedited timeline of 4-5 years, which is faster than the average 10-year timeline for antibiotics.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Bacteriophage therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Tolka AI Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tolka AI Therapeutics.